Shares of Iterum Therapeutics plc (ITRM) dropped Monday after the company announced that it will not get approval for the current form of its new drug application for oral sulopenem. The Food and Drug ...

DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics ...

It has been a roller coaster 2020 so far for nano-cap biotech Iterum Therapeutics (ITRM). Over the past two trading sessions, ITRM shares surged nearly 85% after a regulatory path was outlined for the ...

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company” or "Iterum”), a company focused on delivering next generation oral and IV antibiotics to ...

Iterum Therapeutics ITRM is preparing to release its quarterly earnings on Tuesday, 2025-08-05. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Iterum Therapeutics plc has announced the granting of a non-statutory share option for 200,000 ordinary shares to Christine Coyne, the newly appointed Chief Commercial Officer, as part of her ...

Iterum Therapeutics plc announced the publication of results from its Phase 3 clinical trial, REASSURE, in NEJM Evidence, which evaluated the efficacy of oral sulopenem compared to Augmentin® in ...

DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company” or "Iterum” or "we”), a company focused on delivering next generation oral and IV ...

Iterum Therapeutics set terms Tuesday for its initial public offering, in which the drugmaker could raise up to $85.3 million. The company, which is developing sulopenem antibiotic that could ...

On Friday, Iterum Therapeutics plc (NASDAQ:ITRM) received FDA approval for its Orlynvah (sulopenem etzadroxil and probenecid) for uncomplicated urinary tract infections (uUTIs) caused by the ...